Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Non-steroidal mineralocorticoid receptor antagonists in heart failure

Nature Reviews Cardiology volume 20, pages 645–646 (2023)Cite this article

Subjects

Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Evidence for the use of non-steroidal MR antagonists in HF.

References

  1. McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Butler, J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43, 416–426 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Agarwal, R. et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42, 152–161 (2021).

    Article  CAS  PubMed  Google Scholar 

  4. Pitt, B. et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453–2463 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Filippatos, G. et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 37, 2105–2114 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).

    Article  CAS  PubMed  Google Scholar 

  7. Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252–2263 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474–484 (2022).

    Article  CAS  PubMed  Google Scholar 

  9. Filippatos, G. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur. J. Heart Fail. 24, 996–1005 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Filippatos, G. et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145, 437–447 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School, Athens, Greece

    Gerasimos Filippatos & Dimitrios Farmakis

Authors
  1. Gerasimos Filippatos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Farmakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerasimos Filippatos.

Ethics declarations

Competing interests

G.F. has received consultancy and/or lecture fees and/or is a committee member in trials sponsored by Bayer, Boehringer Ingelheim, Impulse Dynamics, Medtronic, Novartis and Servier. D.F. has received consultancy and/or lecture fees from Bayer, Boehringer Ingelheim and Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filippatos, G., Farmakis, D. Non-steroidal mineralocorticoid receptor antagonists in heart failure. Nat Rev Cardiol 20, 645–646 (2023). https://doi.org/10.1038/s41569-023-00922-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-023-00922-x

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing